

## 1                    **Emergence of the Novel Sixth *Candida auris* Clade VI in Bangladesh**

2    Tahsin Khan<sup>1</sup>, Naimul Islam Faysal<sup>1</sup>, Md Mobarok Hossain<sup>1</sup>, Syeda Mah-E-Muneer<sup>2</sup>, Arefeen

3    Haider<sup>1</sup>, Shovan Basak Moon<sup>1</sup>, Debashis Sen<sup>3</sup>, Dilruba Ahmed<sup>3</sup>, Lindsay A. Parnell<sup>4</sup>,

4    Mohammad Jubair<sup>1</sup>, Nancy A. Chow<sup>4</sup>, Fahmida Chowdhury<sup>2</sup>, Mustafizur Rahman<sup>1,2</sup>

5

6    <sup>1</sup>Genome Centre, Infectious Diseases Division, icddr,b, Mohakhali, Dhaka-1212, Bangladesh

7    <sup>2</sup>Emerging Infections, Infectious Diseases Division, icddr,b, Mohakhali, Dhaka-1212,

8    Bangladesh

9    <sup>3</sup>Mycology Laboratory, icddr,b, Mohakhali, Dhaka-1212, Bangladesh

10   <sup>4</sup>Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia,

11   USA

12

13   Correspondence to:

14   Mustafizur Rahman, PhD, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh;

15   mustafizur@icddr.org; Telephone number: +880 2 9840523-32

16

### 17   **ABSTRACT**

18   *Candida auris*, initially identified in 2009, has rapidly become a critical concern due to its

19   antifungal resistance and significant mortality rates in healthcare-associated outbreaks. To date,

20   whole-genome sequencing (WGS) has identified five unique clades of *C. auris*, with some

21   strains displaying resistance to all primary antifungal drug classes. In this study, we presented

22   the first WGS analysis of *C. auris* from Bangladesh, describing its origins, transmission

23   dynamics, and antifungal susceptibility testing (AFST) profile. Ten *C. auris* isolates collected

24   from hospital settings in Bangladesh were initially identified by CHROMagar™ *Candida* Plus,

25   followed by VITEK®2 system and later sequenced using Illumina NextSeq 550 system.

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

26 Reference-based phylogenetic analysis and variant calling pipelines were used to classify the  
27 isolates in different clades. All isolates aligned ~90% with the Clade I *C. auris* B11205  
28 reference genome. Of the ten isolates, eight clustered with Clade I isolates, highlighting a South  
29 Asian lineage prevalent in Bangladesh. Remarkably, the remaining two isolates formed a  
30 distinct cluster, exhibiting >42,447 SNP differences compared to their closest Clade IV  
31 counterparts. This significant variation corroborates the emergence of a sixth clade (Clade VI)  
32 of *C. auris* in Bangladesh, with potential for international transmission. AFST results showed  
33 that 80% of the *C. auris* isolates were resistant to fluconazole and voriconazole, whereas Clade  
34 VI isolates were susceptible to azoles, echinocandins, and pyrimidine analogue. Genomic  
35 sequencing revealed *ERG11\_Y132F* mutation conferring azole resistance while *FCYI\_S70R*  
36 mutation found inconsequential in describing 5-flucytosine resistance. Our study underscores  
37 the pressing need for comprehensive genomic surveillance in Bangladesh to better understand  
38 the emergence, transmission dynamics, and resistance profiles of *C. auris* infections. Unveiling  
39 the discovery of a sixth clade (Clade VI) accentuates the indispensable role of advanced  
40 sequencing methodologies.

41

## 42 **IMPORTANCE**

43 *Candida auris* is a nosocomial fungal pathogen which is commonly misidentified as other  
44 *Candida* species. Since its emergence in 2009, this multi-drug resistant fungus has become one  
45 of the five urgent antimicrobial threat by 2019. Whole Genome Sequencing (WGS) has proven  
46 to be the most accurate identification technique of *C. auris* which also played a crucial role in  
47 the initial discovery of this pathogen. WGS analysis of *C. auris* has revealed five distinct clades  
48 where isolates of each clade differ among themselves based on pathogenicity, colonization,  
49 infection mechanism as well as other phenotypic characteristics. In Bangladesh, *C. auris* was  
50 1<sup>st</sup> reported in 2019 from clinical samples of a large hospital of Dhaka city. To understand the

51 origin, transmission dynamics and antifungal resistance profile of *C. auris* isolates circulating  
52 in Bangladesh, we conducted WGS based surveillance study on two of the largest hospital  
53 settings in Dhaka, Bangladesh.

54

## 55 INTRODUCTION

56 *Candida auris*, an emerging multidrug-resistant pathogen, imposes a serious threat to global  
57 public health owing to its high virulence and transmissibility in hospital settings [1]. Since the  
58 first report in 2009 in Japan, this nosocomial pathogen has already been reported in over 50  
59 countries, colonizes human skin and hospital environments, and causes invasive candidiasis,  
60 especially in critically ill and immunosuppressed patients [2-4]. Patients with *C. auris* infection  
61 or colonization frequently exhibit other underlying health conditions and comorbidities, such  
62 as diabetes, cardiovascular diseases, liver diseases, chronic or acute kidney failure, solid tumor  
63 or malignancies [5].

64 Whole-genome sequencing (WGS) and matrix-assisted laser desorption ionization–time of  
65 flight (MALDI-TOF MS) platforms are the best-suited options to correctly identify *C. auris*  
66 [6]. Worldwide, WGS analysis has grouped *C. auris* into five distinct genotypic clades based  
67 on 40,000 to >200,000 single nucleotide polymorphism (SNPs) such as Clade I (South Asia),  
68 Clade II (East Asia), Clade III (Africa), Clade IV (South America), and Clade V (Iran) [3, 7,  
69 8]. Though the reasons for the reported independent and simultaneous emergence in different  
70 geographical regions are unknown, animal reservoirs and environmental changes are  
71 speculated to accelerate this situation [9]. Each clade harbors highly related isolates due to local  
72 transmission and clonal expansion within countries [10, 11]. However, analysis from molecular  
73 epidemiological investigations, outbreaks, and individual cases also revealed genetic  
74 complexity suggesting multiple introductions followed by local transmissions in different  
75 countries [12].

76 Antifungal resistance seems to be clade specific [13]. Clade II isolates are generally more  
77 susceptible to antifungal agents, whereas Clade I, III and IV are highly resistant [1, 8, 14]. Only  
78 2/5 identified isolates of Clade V were found resistant to fluconazole but were susceptible to  
79 triazoles, echinocandins, and amphotericin B [15, 16]. Nonetheless, antifungal resistances were  
80 observed on all five clades to currently used antifungal drugs such as azoles (fluconazole,  
81 voriconazole, itraconazole, and isavuconazole), polyenes (amphotericin B), echinocandins  
82 (caspofungin, micafungin, and anidulafungin), and pyrimidine analogue flucytosine [11, 17-  
83 19]. Genomic level inspections revealed clade-specific azole-resistant mutations in *ERG11*:  
84 Y132F or K143R in Clade I, F126T/L in Clade III, Y132F in Clade IV, and Clade V [3, 7].  
85 Numerous mechanisms responsible for antifungal resistance have been reported for *C. auris*,  
86 such as echinocandin-resistant *FKSI*:S639/F/P/Y, and *FKSI*:S635Y/P mutations, 5-flucytosine  
87 resistant *FCY1*:S70R, *FCY2*:M128fs (frameshift), *ADE17*:G45V and *FURI*:1Δ33 [20, 21].  
88 Resistance mechanisms for amphotericin B are not well documented; however, WGS analysis  
89 has identified several nonsynonymous polymorphisms that might infer resistance [22].  
90 Bangladesh (BD) is located in South Asia where fungal outbreaks have been widely reported  
91 [23-25]. The first reported case of *C. auris* in Bangladesh was in 2019, whereas India and  
92 Pakistan reported in 2013 and 2015 respectively [7, 26, 27]. Dutta et al., 2019 reported *C. auris*  
93 infections in 19 patients that showed resistance to voriconazole (18/21), fluconazole (14/21),  
94 and amphotericin B (5/21) [28]. A recent study that conducted AFST for major fungal  
95 pathogens in different hospital settings in Bangladesh also reported *C. auris* resistance against  
96 fluconazole (100%), itraconazole (100%), voriconazole (33.3%), and amphotericin B (100%)  
97 [29]. Monitoring the circulating clades and observing the resistance pattern of *C. auris* is  
98 crucial to prevent spread and transmission. Considering the absence of genomic surveillance  
99 data for *C. auris* in Bangladesh, we conducted WGS analysis on 10 *C. auris* isolates collected  
100 from intensive Care unit (ICU) and neonatal intensive care unit (NICU) patients from two

101 national hospitals in Bangladesh. We report the emergence of a sixth clade (Clade VI),  
102 circulating along with Clade I isolates in Bangladesh.

103

## 104 **RESULTS**

### 105 **Patient Information.**

106 Ten *C. auris* isolates representing eight ICU patients and two NICU patients were described in  
107 this study. Patients were admitted with various underlying health complications; none had  
108 candidemia (**File S1**). Among the patients, only one patient (101022) from ICU had previous  
109 travel history to the United Arab Emirates within one year of enrolment. Overall, 40% (4  
110 patients from ICU) developed nosocomial colonization with *C. auris*, and none received any  
111 antifungal treatment since patients either expired or were discharged by the time the test result  
112 was released (Table 1).

113 **TABLE 1:** Patient metadata of sequenced *Candida auris* isolates.

114

### 115 **WGS SNP Calling and Phylogeny Analysis: Emergence of a Novel Clade.**

116 Whole genome-based SNP calling was performed to distinguish all BD isolates in different  
117 clades, incorporating a total of 25 *C. auris* isolates that represent the known five clades (**File**  
118 **S2**). Around 92.68% (SD  $\pm 1.17$ ) reads of BD isolates mapped with the reference B11205 with  
119 an average GC content of 44.41% (SD  $\pm 0.15$ ) (**File S3**). Phylogenetic analysis revealed that  
120 BD-ICU isolates (Sample ID 101019, 101008, 101009, 101022, 101077, 101082, 101101, and  
121 101087) clustered closely with Clade I with a maximum SNP difference of 163 SNPs (Fig. 1,  
122 **File S4**). Notably, these isolates differed by only  $\leq 17$  SNPs from each other except isolates  
123 101019 and 101022. The isolate (101022) collected from the ICU patient who traveled to UAE  
124 was separated by only 18 SNPs from the UAE\_B14000 isolate. Isolate 101019 had the highest  
125 SNP differences with other Clade I BD-ICU isolates (87-102 SNPs). Within the Clade I

126 clusters, Clade I BD isolates had closer resemblance to UK\_15B5 isolate (51-86 SNPs) than  
127 those from India (108-155 SNPs), Pakistan (109-148 SNPs) and New Jersey, USA (124-163).  
128 Interestingly, the BD-NICU isolates (102096, and 102170) clustered separately from all known  
129 clade isolates (Fig. 1). These two isolates differed by only 68 SNPs and were genetically  
130 distinct from all the clades by at least 42,447 single-nucleotide polymorphisms, and hence,  
131 formed a novel clade, Clade VI [7]. South American Clade (Clade IV) was the closest neighbor  
132 (>42,447 SNPs) for Clade VI, whereas the Iranian Clade (Clade V) was the most distant  
133 neighbor (>254,068 SNPs). To pinpoint the origin of this novel clade, we inquired the neonates'  
134 parents about any international travel history, but none had any in 2020 or before. The two  
135 neonates were born in different hospitals, but later they were transferred to the NICU of study  
136 hospital. It was unknown whether their parents were suffering from fungal colonization or  
137 infections; or whether these neonates acquired *C. auris* colonization during birth or from the  
138 previous hospitals. To investigate the emergence of this novel clade, phenotypic differences  
139 between the Clade I and Clade VI isolates were observed and are described in Table 2 (**Fig S1**).

140

141 **TABLE 2:** Phenotypic differences observed between BD Clade I and Clade VI isolates of  
142 *Candida auris* at different timelines (A) 24 hours (B) 48 hours and (C) 72 hours.

143

144 **FIG 1.** Phylogenetic tree based on SNPs of 35 *C. auris* isolates. (A) Representation of known  
145 five clades with novel Clade VI of *C. auris*. (B) Distances between Clade IV and novel Clade  
146 VI. All the BD isolates from our study are represented by dark blue color. Eight BD-ICU  
147 isolates clusters with reference isolate and 5 Clade I isolates from different countries. Two BD-  
148 NICU isolate (102096, and 102170) clusters together distinctly from other clades forming  
149 novel Clade VI. Isolate B11243 of Clade IV has the closest SNP distances from Clade VI

150 isolates. (C) Clade-wise heatmap of SNP distances among all *C. auris* isolates used in this  
151 study.

152

### 153 **Molecular Resistance Mechanisms.**

154 All the BD isolates were screened for mutations associated with antifungal resistance. For  
155 fluconazole and other triazole resistance, *ERG11*, *CDR1*, *TAC1B* and *MRR1A* gene mutations  
156 were screened in several positions leading to increased MIC values. All BD-ICU isolates of  
157 Clade I harbored *ERG11\_Y132F* substitution. No mutations were detected in *CDR1*, *TAC1B*  
158 and *MRR1A* genes. No known *FKSI* gene mutation was observed in BD-ICU isolates which is  
159 reflected by susceptibility to caspofungin in AFST results (Table 3). *FCYI\_S70R* mutation  
160 which confers 5-flucytocine resistance was detected in all BD-ICU isolates by genomic  
161 analysis. No known mutations in *ERG3* and *ERG6* genes were detected which could explain  
162 the amphotericin B resistance in isolate 101022. Surprisingly, Clade VI isolates from BD-  
163 NICU patients had no known mutations in any of the drug resistance genes (Table 3).

164

165 **TABLE 3:** Results of known mutation analysis and antifungal susceptibility test for azoles,  
166 polyenes, and echinocandins.

167

### 168 **Antifungal Susceptibility Testing (AFST).**

169 Antifungal susceptibility testing was performed on all BD *C. auris* isolates against fluconazole,  
170 voriconazole, caspofungin, and amphotericin B (Table 3). Based on U.S. CDC tentative  
171 breakpoints, all BD-ICU isolates were highly resistant to fluconazole (MIC 256 mg/L) and  
172 voriconazole (MIC 32 mg/L). Isolate 101022 collected from patient with recent travel history  
173 to the United Arab Emirates additionally showed resistance to amphotericin B (MIC 2 mg/L)  
174 along with fluconazole and voriconazole. No resistance was observed for caspofungin in BD-

175 ICU isolates. On the contrary, BD-NICU isolates representing Clade VI were susceptible to 3  
176 major antifungal drug classes. However, BD-NICU isolate 102170 demonstrated resistance to  
177 amphotericin B (MIC 2 mg/L). Only isolate 101019 of Clade I harboring *FCYI\_S70R* mutation  
178 showed resistance against 5-flucytosine in both disk diffusion and automated VITEK<sup>®</sup>2  
179 methods, while other Clade I isolates showed sensitivity in both methods even though these  
180 harbor the same mutation (Table 4). Mutational analysis on the resistance profile aligned with  
181 the AFST results except for isolate 101022 and 102170; no known mutation was found that  
182 confer amphotericin B resistance.

183

184 **TABLE 4:** Results of 5-flucytosine antifungal susceptibility test by disk diffusion and  
185 VITEK<sup>®</sup>2 method.

186

## 187 **DISCUSSION**

188 *Candida auris*, first detected in Bangladesh in 2019, has emerged as a global multi-drug  
189 resistant healthcare-associated pathogen [29]. WGS-based approach revealed the circulation of  
190 Clade I lineages, and the emergence of a new Clade VI in Bangladesh. Six BD-ICU Clade I  
191 isolates (101008, 101009, 101077, 101082, 101101, 101087) collected from adult patients, who  
192 never traveled overseas, are phylogenetically closest to each other (SNPs range 3-17),  
193 indicating the ongoing local and clonal transmission [12, 30]. The isolate 101022 from an ICU  
194 patient who previously traveled to UAE and died after admission was only 18 SNPs different  
195 than UAE\_B14000, indicating possible Clade I transmission from UAE to Bangladesh.

196 The genome sequencing approach separated the clades of *C. auris* by tens of thousands of SNP  
197 differences [7]. The ~42,447 SNPs difference of BD-NICU isolates (102096 and 102170)  
198 indicate the emergence of the new clade, Clade VI, in Bangladesh. Though tracing was not  
199 possible to identify the source of this nosocomial infection in neonates, it is evident that Clade



200 VI is circulating in Bangladesh. By the time of writing this manuscript, a preprint published by  
201 a group of researchers from Singapore claimed the presence of a new clade separated by  
202 >36,000 SNPs from all known five clades of *C. auris* [31]. These isolates namely isolate A  
203 (LIMS ID F3485, Biosample SAMN36753178), Isolate B (LIMS ID F1580, Biosample  
204 SAMN36753179), Isolate C (LIMS ID F0083, Biosample SAMN36753180), and 102096 from  
205 our study (SRR24877248) were distinct by at least 70 SNPs [31]. Isolate C of the novel clade  
206 was collected from the blood of a Bangladeshi patient in 2018, who was airlifted directly to  
207 Singapore General Hospital to have treatment, and was initially classified as Clade IV [30].  
208 The presence of candidemia in this patient indicates the undetected circulation of novel *C. auris*  
209 clade in Bangladesh and a later transfer to Singapore in 2018 before the first detection of *C.*  
210 *auris* in Bangladesh in 2019 [28]. It is surprising to note that even though Clade I and Clade  
211 VI isolates are circulating in Bangladesh simultaneously, Clade VI isolates acquired no known  
212 mutations and showed no phenotypic resistance except amphotericin B (Isolate 102170). It is  
213 of utmost importance to conduct nationwide genomic surveillance of prospectively collected  
214 *C. auris* isolates along with archived isolates stored at different hospitals in Bangladesh to  
215 understand the origin and transmission dynamics of Clade VI.

216 Clade I BD-ICU isolates showed the general trend of azole resistance for both mutational  
217 (genotypic) and AFST (phenotypic) results against fluconazole and voriconazole [7].  
218 Surprisingly, these isolates showed inconsistency for 5-flucytosine resistance pattern except  
219 for isolate 101019. A similar observation was reported from a 29-year-old woman residing in  
220 New Jersey, who was diagnosed with severe short bowel syndrome [20]. She underwent a  
221 multi-visceral transplantation surgery and during her post-operative period of 72 days, the  
222 patient developed refractory fungal peritonitis. Nineteen *C. auris* isolates were obtained from  
223 the patient at various time intervals. While the initial 12 isolates collected within the initial 33  
224 days demonstrated sensitivity to 5-flucytosine, the subsequent 7 isolates obtained between days

225 33 and 72 exhibited resistance to this antifungal agent. Genomic analysis of these isolates  
226 revealed the presence of the *FCYI\_S70R* mutation in all 19 isolates. The authors argued  
227 *FCYI\_S70R* mutation to be inconsequential in describing 5-flucytosine resistance. The  
228 findings in our study reflected the discrepancy between *FCYI\_S70R* mutation and resistance  
229 pattern for Clade I isolates, strengthening the argument of inconsequential behavior of  
230 *FCYI\_S70R* mutation in describing the 5-flucytosine resistance. Two BD-NICU isolates  
231 representing Clade VI exhibited no resistance to the antifungals tested (except amphotericin B  
232 for Isolate 102170) and harbored no known mutations conferring resistance. Active clinical  
233 surveillance, monitoring of clinical symptoms, and extensive epidemiological investigation  
234 will accelerate understanding of the significance of this newly discovered sixth clade of *C.*  
235 *auris*.

236

## 237 **LIMITATIONS**

238 Our study presents the WGS-based approach to detect the circulation of *C. auris* clades for the  
239 first time in Bangladesh. The isolates sequenced in this study were collected from the archived  
240 samples in 2021, as part of regular surveillance to monitor infections and colonization  
241 associated with ICU/NICU admitted patients, tracing the contacts of *C. auris* positive cases  
242 was not performed at that time. The small sample size in this study may not be the  
243 representative picture of *C. auris* circulation in Bangladesh. Including a large sample size  
244 would increase the chances of capturing other undetected clades circulating in Bangladesh.  
245 Long-read sequencing would ensure the recovery of the nearly full genome and the  
246 comprehensive genomic study on the antifungal resistance profile. Overall, our study  
247 demonstrates the necessity of *C. auris* genomic surveillance to understand the transmission  
248 dynamics, pathobiology and containment of this urgent antimicrobial-resistant threat in  
249 Bangladesh.

250

## 251 CONCLUSION

252 We report the circulation of Clade I *C. auris* in Bangladesh along with the emergence of the  
253 novel Clade VI detected patients in the ICU and NICU. Bangladesh remains the hub of this  
254 novel clade since a Clade VI isolate was also found in the blood of a Bangladeshi patient  
255 airlifted in Singapore in 2018. It is critical that we enforce nation-wide genomic surveillance  
256 to better understand the emergence and transmission of this novel clade in Bangladesh.

257

## 258 MATERIALS AND METHODS

### 259 Isolate Selection.

260 From August-September 2021, as part of ongoing hospital surveillance, we identified a total of  
261 60 *Candida auris* isolates and archived these isolates at the International Centre for Diarrhoeal  
262 Disease Research, Bangladesh (icddr,b) Mycology Laboratory. Isolates were cultured from  
263 skin swab samples from both axilla and groin for screening the patients admitted in the ICU  
264 and NICU of two tertiary care hospitals (one public and one private). In addition to on-  
265 admission screening sample, subsequent follow up samples were collected- after 72 hours of  
266 admission and before shifting from ICU- from patients to identify nosocomial colonization.  
267 [32]. Isolates from ICU patients were termed as BD-ICU, and isolates from NICU patients  
268 were termed BD- NICU throughout the manuscript.

### 269 DNA Extraction and Whole Genome Sequencing.

270 Ten *C. auris* isolates were randomly selected and retrieved from  $-80^{\circ}\text{C}$  storage and grown on  
271 CHROMagar<sup>TM</sup> Candida Plus media for presumptive identification of *C. auris*. Pure *C. auris*  
272 colonies were transferred from CHROMagar<sup>TM</sup> plate to SDA plate and incubated at  $37^{\circ}\text{C}$  for  
273 72 hours. Genomic DNA of the *C. auris* isolates was extracted using the Qiagen DNAeasy  
274 Blood & Tissue Kit, and the Illumina DNA Prep kit (Illumina Inc., San Diego, California, USA)

275 was used for the construction of DNA libraries. Sequencing was performed on Illumina  
276 NextSeq 550 platform with 2x150 bp cycles at icddr,b Genome Centre.

### 277 **Variant Calling and Phylogenetic Analysis.**

278 To investigate the origin and possible route of transmission of sequenced *C. auris* isolates from  
279 Bangladesh, phylogenetic analysis was performed using the whole-genome sequences. A total  
280 of 25 isolates representative of *C. auris* clades I – V were also included in this analysis (**File**  
281 **S2**). Quality control, single nucleotide polymorphism (SNP) calling, and phylogenetic analysis  
282 were performed using the reference-based pipeline, MycoSNP, v1.4  
283 (<https://github.com/CDCgov/mycosnp-nf>) with default parameters and using assembly B11205  
284 (Accession no. GCA\_016772135.1) generated from an isolate from India [33]. In brief, the  
285 MycoSNP workflow masks repetitive regions and indexes the reference genome in preparation  
286 for read alignment and snp calling. Paired-end reads were trimmed and filtered for low quality  
287 data. Samples, with at least 20X coverage and a % GC content between 42-47.5%, were used  
288 for alignment to the reference genome using the BWA [34] and pre-processed for downstream  
289 single-nucleotide polymorphism (SNP) analysis using GATK[35]. GATK *HaplotypeCaller*  
290 function is used for haplotype calling the processed BAM files from each isolate. The ploidy  
291 parameter for *C. auris* is set to haploid. *HaplotypeCaller* uses the PairHMM (Pair Hidden  
292 Markov Models) algorithm and performs pairwise alignment. Then, the resulting individual  
293 gVCF files are merged into a single multi-sample gVCF file by *CombineGVCFs* function.  
294 Next, the *GenotypeGVCFs* function performs SNP calling from this single gVCF file which  
295 results in a VCF file with all samples genotyped. GATK's *VariantFiltration* function was used  
296 to filter SNP sites based on the QualityByDepth (QD), FisherStrand Score (FS) and  
297 RMSMappingQuality (MQ) parameters using filtering expression: "QD < 2.0 || FS > 60.0 ||  
298 MQ < 40.0". Additional customized SNP filters were applied based on parameters such as  
299 Genotype Quality (GQ), allele depth (AD), and depth (DP) using following criterion: : GQ ≥

300 50, AD  $\geq$  80%, DP  $\geq$  10. The MycoSNP workflow recovered all SNP alleles from the VCF files  
301 using a Python script “vcfSnpsToFasta.py” ([https://github.com/broadinstitute/broad-](https://github.com/broadinstitute/broad-fungalgroup/tree/master/scripts/SNPs)  
302 [fungalgroup/tree/master/scripts/SNPs](https://github.com/broadinstitute/broad-fungalgroup/tree/master/scripts/SNPs)) to create an SNP alignment in multi-fasta format [33].

303 To construct Maximum Likelihood (ML) phylogenetic trees from SNP alignment, RAxML  
304 v8.2.12 [36] was utilized with the Generalized Time-Reversible model and a Gamma  
305 distribution (GTRGAMMA) to account for site-specific rate variation. Support for the ML  
306 phylogenetic trees were evaluated through 1000 bootstrap replicates of the alignment. The  
307 resulting trees were visualized using iTol v5.5 [37].

### 308 **Mutational Characterization.**

309 *De novo* assembly was performed using SPAdes v.3.15.5 to generate assemblies and assessed  
310 with Quast v.5.5.0 [38, 39]. The assembly reports were summarized in **File S5** in the  
311 supplemental material. A custom python script was generated to map *ERG11* (F126L, Y132F,  
312 K143R, and F444L), *CDR1* (V704L), *TAC1B* (S611P) and *MRR1A* (N647T) for azole  
313 resistance, *FCY1* (S70R) and *FUR1* (1 $\Delta$ 33, and F211I) for 5-flucytocine resistance and *FKSI*  
314 (S639Y/P/F, and F635C) genes for echinocandin resistance. Since the molecular mechanism  
315 of amphotericin B is not well established, we also investigated known mutations in *ERG3*  
316 (S58T) and *ERG6* (G403T, and R97fs) genes involved in ergosterol biosynthetic pathways  
317 which are postulated to confer amphotericin B resistance [14, 40].

### 318 **Antifungal Susceptibility Testing (AFST).**

319 To assess the resistance of *C. auris* to antifungals, antifungal susceptibility testing (AFST) was  
320 performed using Gradient Diffusion Strips method or E-test (OFD-500-P03:  
321 <https://www.cdc.gov/fungal/lab-professionals/pdf/afst-yeasts-h.pdf>) according to Clinical and  
322 Laboratory Standards Institute (CLSI) guidelines [41]. The E-test gradient strips of  
323 fluconazole, voriconazole, caspofungin, and amphotericin B was obtained from Biomerieux.  
324 The reference number and lot number of corresponding anti-fungal strip are provided in **File**

325 **S6.** The fluconazole concentration gradient ranged from 256 to 0.016 µg/ml while for other  
326 antifungals, it ranged from 32 to 0.002 µg/ml. The antifungals used in this study for AFST are  
327 representative of 3 major classes of antifungals (azoles, echinocandins and polyenes). The  
328 culture media used were Sabouraud dextrose agar (SDA; Becton Dickinson) and Roswell Park  
329 Memorial Institute medium 1640 (RPMI-1640; Sigma–Aldrich). Currently, there are no  
330 established minimum inhibition concentration (MIC) breakpoints for *C. auris*. CDC proposed  
331 tentative breakpoints for fluconazole ( $\geq 32$  mg/L), voriconazole ( $\geq 1$ mg/L), caspofungin ( $\geq 2$   
332 mg/L), anidulafungin ( $\geq 4$  mg/L), micafungin ( $\geq 4$  mg/L), amphotericin B ( $\geq 2$  mg/L) and other  
333 antifungals [7, 18, 42].

334 The *C. auris* isolates from this study were also tested for susceptibility to 5-flucytosine by disk  
335 diffusion method outlined by CLSI-M60 guidelines [43]. The assays were performed using  
336 fungal suspension adjusted to match the turbidity of a 0.5 McFarland standard. The antifungal  
337 disk for Flucytosine (AFY) 10 µg was purchased from Liofilchem<sup>®</sup>, Italy). Mueller Hinton II  
338 Agar (MHA; BD), Sabouraud Dextrose Agar (SDA; BD) and Roswell Park Memorial Institute  
339 Medium 1640 (RPMI-1640; Sigma–Aldrich) was used for preparation of media of the *C. auris*  
340 isolates. The reference and lot number of corresponding agar and media are provided in **File**  
341 **S6.** The disks were placed on to the inoculum media and the plates were incubated at  
342 35<sup>0</sup>C(±2<sup>0</sup>C) for 18-24 hours. After 24 hours, the plates were examined and the zones of  
343 inhibition diameter (ZOD) around the discs were measured in millimeters (mm). The inhibition  
344 zone diameters (mm) were interpreted as Susceptible (S), Intermediate (I) and Resistant (R)  
345 based on established clinical breakpoints provided by CLSI. Susceptibility to 5-flucytosine was  
346 also tested via automated VITEK<sup>®</sup>2 system using an AST-YS09 card as per the manufacturer's  
347 instructions. The time and temperature of incubation was similar to disk diffusion assay  
348 (18 – 24 hours at 35±2<sup>0</sup>C) but the results were expressed as MICs. The MIC calling range  
349 was 1 to 64 mg/L for 5-flucytosine. Since the VITEK<sup>®</sup>2 system lacks species-specific MICs

350 for *C. auris*, the species was modified to different *Candida* spp. to obtain MICs for *C. auris*  
351 isolates. Notably, the MIC values remained consistent irrespective of the species assigned when  
352 retrieving MIC data for *C. auris* across all drugs. As *C. duobushaemulonii* closely related to *C.*  
353 *auris* and belongs to the *C. haemulonii* complex, analysis was based on MICs retrieved from  
354 this species [44, 45].

355

### 356 **Ethical approval.**

357 The study was approved by icddr,b Research Review Committee and Ethical Review  
358 Committee. The approval protocol number was PR-20122. All patients participated in this  
359 study gave written informed consent for donating the samples.

### 360 **Data availability.**

361 The sequencing data sets generated during this study are available in the Sequence Read  
362 Archive repository under projects PRJNA981511.

### 363 **ACKNOWLEDGMENTS**

364 The study was funded by Centre for Disease Control and Prevention, Atlanta, USA, through  
365 cooperative agreement. We also gratefully acknowledge icddr,b core donors (Govt. of  
366 Bangladesh and Canada) for their unrestricted support and commitment to icddr,b's research  
367 efforts.

368

369 Conceptualization, T.K., N.I.F., M.J., F.C., and M.R.; data curation, T.K., N.I.F., M.M.H., S.M.,  
370 A.H., and D.S.; formal analysis, T.K., N.I.F., M.M.H., A.H., S.B.M., D.S., and L.A.P.;  
371 investigation, T.K., N.I.F., S.M., DA, M.J., N.A.C., F.C., and M.R.; methodology, T.K., N.I.F.,  
372 M.M.H., A.H., S.B.M., DA, L.A.P., and M.J.; validation, T.K., N.I.F., A.H., S.B.M., D.S., DA,  
373 L.A.P., M.J., F.C., and M.R.; supervision, F.C., and M.R.; visualization, T.K., M.M.H., L.A.P.,

374 and N.A.C.; writing - original draft, T.K., N.I.F., and M.R.; writing -review & editing, T.K.,  
375 N.I.F., M.M.H., S.M., A.H., S.B.M., D.S., DA, L.A.P., M.J., N.A.C., F.C., and M.R.

376

377 **Disclaimer:** The findings and conclusions of this report are those of the authors and do not  
378 necessarily represent the official position of the Centers for Disease Control (CDC). The  
379 Sample IDs and Sequencing IDs used in this manuscript were randomly assigned, did not  
380 correspond to any of the hospital generated original IDs and were not disclosed to anyone  
381 outside the research group, not even to hospital staff or patients themselves.

382

### 383 **Supplemental Material**

384 **Fig S1:** Phenotypic differences observed between BD Clade I and Clade VI isolates of *Candida*  
385 *auris* at different timelines (A) 24 hours (B) 48 hours and (C) 72 hours.

386 **File S1:** Patient metadata of BD *Candida auris* isolates.

387 **File S2:** *Candida auris* isolates used in this representing known five clades.

388 **File S3:** Quality metrics of BD *Candida auris* isolates generated by MycoSNP v1.4.

389 **File S4:** SNP distances generated by MycoSNP v1.4 for all *Candida auris* isolates in this study.

390 **File S5:** Assembly metrics of BD *Candida auris* isolates.

391 **File S6:** Anti-fungal strips, agar, and media used in this study with reference number and lot  
392 number.

393

### 394 **REFERENCES**

- 395 1. Muñoz, J.F., et al., *Genomic insights into multidrug-resistance, mating and virulence in*  
396 *Candida auris and related emerging species*. Nature communications, 2018. **9**(1): p.  
397 5346.
- 398 2. Satoh, K., et al., *Candida auris sp. nov., a novel ascomycetous yeast isolated from the*  
399 *external ear canal of an inpatient in a Japanese hospital*. Microbiology and  
400 immunology, 2009. **53**(1): p. 41-44.
- 401 3. Spruijtenburg, B., et al., *Confirmation of fifth Candida auris clade by whole genome*  
402 *sequencing*. Emerging Microbes & Infections, 2022. **11**(1): p. 2405-2411.



- 403 4. Chowdhary, A., et al., *Multidrug-resistant Candida auris infections in critically ill*  
404 *coronavirus disease patients, India, April–July 2020*. *Emerging infectious diseases*,  
405 2020. **26**(11): p. 2694.
- 406 5. Osei Sekyere, J., *Candida auris: A systematic review and meta-analysis of current*  
407 *updates on an emerging multidrug-resistant pathogen*. *Microbiologyopen*, 2018. **7**(4):  
408 p. e00578.
- 409 6. Lockhart, S.R., M.M. Lyman, and D.J. Sexton, *Tools for detecting a “superbug”: updates*  
410 *on Candida auris testing*. *Journal of Clinical Microbiology*, 2022. **60**(5): p. e00808-21.
- 411 7. Lockhart, S.R., et al., *Simultaneous emergence of multidrug-resistant Candida auris on*  
412 *3 continents confirmed by whole-genome sequencing and epidemiological analyses*.  
413 *Clinical Infectious Diseases*, 2017. **64**(2): p. 134-140.
- 414 8. Chow, N.A., et al., *Tracing the evolutionary history and global expansion of Candida*  
415 *auris using population genomic analyses*. *MBio*, 2020. **11**(2): p. 10.1128/mbio.03364-  
416 19.
- 417 9. Forsberg, K., et al., *Candida auris: The recent emergence of a multidrug-resistant*  
418 *fungal pathogen*. *Medical mycology*, 2019. **57**(1): p. 1-12.
- 419 10. Sharma, C., et al., *Whole genome sequencing of emerging multidrug resistant Candida*  
420 *auris isolates in India demonstrates low genetic variation*. *New microbes and new*  
421 *infections*, 2016. **13**: p. 77-82.
- 422 11. Rhodes, J., et al., *Genomic epidemiology of the UK outbreak of the emerging human*  
423 *fungal pathogen Candida auris*. *Emerging microbes & infections*, 2018. **7**(1): p. 1-12.
- 424 12. Chow, N.A., et al., *Multiple introductions and subsequent transmission of multidrug-*  
425 *resistant Candida auris in the USA: a molecular epidemiological survey*. *The Lancet*  
426 *Infectious Diseases*, 2018. **18**(12): p. 1377-1384.
- 427 13. Lockhart, S.R., A. Chowdhary, and J.A. Gold, *The rapid emergence of antifungal-*  
428 *resistant human-pathogenic fungi*. *Nature Reviews Microbiology*, 2023: p. 1-15.
- 429 14. Maphanga, T.G., et al., *In vitro antifungal resistance of Candida auris isolates from*  
430 *bloodstream infections, South Africa*. *Antimicrobial agents and chemotherapy*, 2021.  
431 **65**(9): p. 10.1128/aac.00517-21.
- 432 15. Armaki, M.T., et al., *First fluconazole-resistant Candida auris isolated from fungal otitis*  
433 *in Iran*. *Current medical mycology*, 2021. **7**(1): p. 51.
- 434 16. Safari, F., et al., *A chronic autochthonous fifth clade case of Candida auris otomycosis*  
435 *in Iran*. *Mycopathologia*, 2022. **187**(1): p. 121-127.
- 436 17. Mhlanga, M., et al., *Multilocus sequence typing of azole-resistant Candida auris strains,*  
437 *South Africa*. *Southern African Journal of Infectious Diseases*, 2020. **35**(1): p. 1-7.
- 438 18. Chowdhary, A., et al., *A multicentre study of antifungal susceptibility patterns among*  
439 *350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in*  
440 *azole and echinocandin resistance*. *Journal of Antimicrobial Chemotherapy*, 2018.  
441 **73**(4): p. 891-899.
- 442 19. Berkow, E.L., D. Angulo, and S.R. Lockhart, *In vitro activity of a novel glucan synthase*  
443 *inhibitor, SCY-078, against clinical isolates of Candida auris*. *Antimicrobial agents and*  
444 *chemotherapy*, 2017. **61**(7).
- 445 20. Jacobs, S.E., et al., *Candida auris pan-drug-resistant to four classes of antifungal*  
446 *agents*. *Antimicrobial Agents and Chemotherapy*, 2022. **66**(7): p. e00053-22.
- 447 21. Kordalewska, M., et al., *Understanding echinocandin resistance in the emerging*  
448 *pathogen Candida auris*. *Antimicrobial agents and chemotherapy*, 2018. **62**(6): p.  
449 10.1128/aac.00238-18.

- 450 22. Escandón, P., et al., *Molecular epidemiology of Candida auris in Colombia reveals a*  
451 *highly related, countrywide colonization with regional patterns in amphotericin B*  
452 *resistance*. *Clinical Infectious Diseases*, 2019. **68**(1): p. 15-21.
- 453 23. Gugnani, H.C., et al., *Burden of serious fungal infections in Bangladesh*. *European*  
454 *Journal of Clinical Microbiology & Infectious Diseases*, 2017. **36**: p. 993-997.
- 455 24. Islam, M.T., et al., *Emergence of wheat blast in Bangladesh was caused by a South*  
456 *American lineage of Magnaporthe oryzae*. *BMC biology*, 2016. **14**(1): p. 1-11.
- 457 25. Fisher, M.C., et al., *Threats posed by the fungal kingdom to humans, wildlife, and*  
458 *agriculture*. *MBio*, 2020. **11**(3): p. 10.1128/mbio.00449-20.
- 459 26. Chowdhary, A., et al., *Multidrug-resistant endemic clonal strain of Candida auris in*  
460 *India*. *European journal of clinical microbiology & infectious diseases*, 2014. **33**: p. 919-  
461 926.
- 462 27. Clancy, C.J. and M.H. Nguyen, *Emergence of Candida auris: an international call to*  
463 *arms*. 2017, Oxford University Press US. p. 141-143.
- 464 28. Dutta, S., et al., *Detection of Candida auris and its antifungal susceptibility: first report*  
465 *from Bangladesh*. *IMC Journal of Medical Science*, 2019. **13**(2): p. 18-22.
- 466 29. Sathi, F.A., et al., *Prevalence and antifungal susceptibility of clinically relevant candida*  
467 *species, identification of candida auris and kodamaea ohmeri in Bangladesh*. *Tropical*  
468 *Medicine and Infectious Disease*, 2022. **7**(9): p. 211.
- 469 30. Tan, Y.E., et al., *Candida auris in Singapore: Genomic epidemiology, antifungal drug*  
470 *resistance, and identification using the updated 8.01 VITEK® 2 system*. *International*  
471 *journal of antimicrobial agents*, 2019. **54**(6): p. 709-715.
- 472 31. Suphavilai, C., et al., *Discovery of the sixth Candida auris clade in Singapore*. *medRxiv*,  
473 2023: p. 2023.08.01.23293435.
- 474 32. Roberts, S.C., et al., *Genetic evaluation of nosocomial Candida auris transmission*.  
475 *Journal of clinical microbiology*, 2021. **59**(4): p. 10.1128/jcm.02252-20.
- 476 33. Bagal, U.R., et al., *MycoSNP: a portable workflow for performing whole-genome*  
477 *sequencing analysis of Candida auris*, in *Candida auris: Methods and Protocols*. 2022,  
478 Springer. p. 215-228.
- 479 34. Li, H., *Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM*.  
480 *arXiv preprint arXiv:1303.3997*, 2013.
- 481 35. McKenna, A., et al., *The Genome Analysis Toolkit: a MapReduce framework for*  
482 *analyzing next-generation DNA sequencing data*. *Genome research*, 2010. **20**(9): p.  
483 1297-1303.
- 484 36. Stamatakis, A., *RAxML version 8: a tool for phylogenetic analysis and post-analysis of*  
485 *large phylogenies*. *Bioinformatics*, 2014. **30**(9): p. 1312-1313.
- 486 37. Letunic, I. and P. Bork, *Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic*  
487 *tree display and annotation*. *Nucleic acids research*, 2021. **49**(W1): p. W293-W296.
- 488 38. Bankevich, A., et al., *SPAdes: a new genome assembly algorithm and its applications*  
489 *to single-cell sequencing*. *Journal of computational biology*, 2012. **19**(5): p. 455-477.
- 490 39. Gurevich, A., et al., *QUAST: quality assessment tool for genome assemblies*.  
491 *Bioinformatics*, 2013. **29**(8): p. 1072-1075.
- 492 40. Rybak, J.M., et al., *In vivo emergence of high-level resistance during treatment reveals*  
493 *the first identified mechanism of amphotericin B resistance in Candida auris*. *Clinical*  
494 *Microbiology and Infection*, 2022. **28**(6): p. 838-843.
- 495 41. *Clinical and Laboratory Standards Institute (2008) Reference method for broth dilution*  
496 *antifungal susceptibility testing of yeasts, 3rd ed. Approved standard. CLSI document*

- 497 M27-A3. *Clinical and Laboratory Standards Institute, Wayne*. 2008; 3rd:[Available  
498 from: [https://clsi.org/media/1461/m27a3\\_sample.pdf](https://clsi.org/media/1461/m27a3_sample.pdf).  
499 42. CDC. *Candida auris Antifungal Susceptibility Testing*. 2020; Available from:  
500 <https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html>  
501 43. CLSI, *Performance standards for antifungal susceptibility testing of yeasts*. 2017,  
502 Clinical and Laboratory Standards Wayne, PA.  
503 44. Xie, O., et al., *Candida duobushaemulonii sepsis and Candida auris co-isolation*  
504 *following hospitalisation in Vietnam*. *Pathology*, 2020. **52**(5): p. 590-591.  
505 45. Siopi, M., et al., *Evaluation of the Vitek 2 system for antifungal susceptibility testing of*  
506 *Candida auris using a representative international panel of clinical isolates:*  
507 *overestimation of amphotericin B resistance and underestimation of fluconazole*  
508 *resistance*. *Journal of Clinical Microbiology*, 2024: p. e01528-23.  
509

**TABLE 1:** Patient metadata of sequenced *Candida auris* isolates.

<b>Sample ID</b>	<b>Clade</b>	<b>Patient Age Range (Years)</b>	<b>Collection Source</b>	<b>Collection Date (Year)</b>	<b>Travel History</b>	<b>Colonization Type</b>
101019	Clade I	56-60	ICU	2021	No	HAI
101008	Clade I	41-45	ICU	2021	No	HAI
101009	Clade I	31-35	ICU	2021	No	HAI
101022	Clade I	31-35	ICU	2021	UAE	HAI
101077	Clade I	11-15	ICU	2021	No	On admission
101082	Clade I	21-25	ICU	2021	No	On admission
101101	Clade I	51-55	ICU	2021	No	On admission
101087	Clade I	16-20	ICU	2021	No	On admission
102096	Clade VI	0-5	NICU	2021	No	On admission
102170	Clade VI	0-5	NICU	2021	No	On admission

\*HAI = Hospital acquired infection.

**TABLE 2:** Phenotypic differences observed between BD Clade I and Clade VI isolates of *Candida auris* at different timelines (A) 24 hours (B) 48 hours and (C) 72 hours.

<b>Hour</b>	<b>Colony Characteristics</b>	<b>Clade I</b>	<b>Clade VI</b>	<b>Comments</b>
24	Size	Tiny	Large	Difference in colony morphology
	Morphology	Mated	Isolated	
	Color	Whitish	Whitish Blue	
48	Size	Medium Muroid	Large Muroid	Difference in colony size and color
	Morphology	Isolated	Single Isolated	
	Color	Whitish	Whitish Blue	
72	Size	Large Muroid	Large Muroid	Both Clades show similar characteristics
	Morphology	Single Isolated	Single Isolated	
	Color	Whitish Blue	Whitish Blue	

**TABLE 3:** Results of known mutation analysis and antifungal susceptibility test for azoles, polyenes, and echinocandins.


Sample ID	Clade	Azole		Echinocandin	Polyene	Gene Mutations	
		Fluconazole	Voriconazole	Caspofungin	Amphotericin B	<i>ERG11</i>	<i>FCY1</i>
101019	Clade I	256	32	0.19	1	Y132F	S70R
101008	Clade I	256	32	0.25	1	Y132F	S70R
101009	Clade I	256	32	0.38	1	Y132F	S70R
101022	Clade I	256	32	0.125	2	Y132F	S70R
101077	Clade I	256	32	0.25	0.5	Y132F	S70R
101082	Clade I	256	32	0.19	0.75	Y132F	S70R
101101	Clade I	256	32	0.25	0.5	Y132F	S70R
101087	Clade I	256	32	0.25	1	Y132F	S70R
102096	Clade VI	6	0.19	0.125	0.75	-	-
102170	Clade VI	8	0.19	0.125	2	-	-

**TABLE 4:** Results of 5-flucytosine antifungal susceptibility test by disk diffusion and VITEK<sup>®</sup>2 method.


Sample ID	Clade	Disk Diffusion		VITEK <sup>®</sup> 2		Gene Mutation
		ZOD (mm)	Resistance Profile	MIC (mg/L)	Resistance Profile	<i>FCYI</i>
101019	Clade I	6	R	≥ 64	R	S70R
101008	Clade I	36	S	≤ 1	S	S70R
101009	Clade I	30	S	≤ 1	S	S70R
101022	Clade I	35	S	≤ 1	S	S70R
101077	Clade I	34	S	≤ 1	S	S70R
101082	Clade I	34	S	≤ 1	S	S70R
101101	Clade I	30	S	≤ 1	S	S70R
101087	Clade I	33	S	≤ 1	S	S70R
102096	Clade VI	32	S	≤ 1	S	-
102170	Clade VI	31	S	≤ 1	S	-

\*S = Susceptible, I = Intermediate, R = Resistant. The categorization of resistance was based on established clinical breakpoints provided by CLSI.

A.



B.



C.

